

Frontiers in Clinical Drug Research

(Anti Infectives)



Editor:
Atta-ur-Rahman, *FRS*

Bentham Books

Frontiers in Clinical Drug Research-Anti Infection

(Volume 7)

Edited by

Atta-ur-Rahman, FRS

*Honorary Life Fellow,
Kings College,
University of Cambridge,
Cambridge,
UK*

Frontiers in Clinical Drug Research-Anti Infectives

Volume # 7

Editor: Prof. Atta-ur-Rahman, *FRS*

ISSN (Online): 2352-3212

ISSN (Print): 2452-3208

ISBN (Online): 978-981-4998-09-3

ISBN (Print): 978-981-4998-10-9

ISBN (Paperback): 978-981-4998-11-6

©2021, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 NUCLEIC ACID AND PEPTIDE APTAMERS AS POTENTIAL ANTIVIRAL DRUGS	1
<i>Serap Evran, Özge Uğurlu, Ezgi Man, Merve Gültan and Canan Özyurt</i>	
1. INTRODUCTION	2
1.1. The in vitro Selection Methods for Peptide and Nucleic Acid Aptamers	2
1.2. MRNA Display	3
1.3. Ribosome Display	5
1.4. SELEX (Systematic Evolution of Ligands by Exponential Enrichment) for Nucleic Acid Aptamers	6
1.4.1. Cell-SELEX	8
1.4.2. Bead-Based SELEX	9
1.5. Post-SELEX Modifications	9
1.6. Modification of Peptide Aptamers for Therapeutic Applications	10
2. APTAMERS IN VIRAL DIAGNOSIS	10
2.1. Aptamers in Diagnosis of Hepatitis B Virus (HBV)	11
2.2. Aptamers in Diagnosis of Hepatitis C Virus (HCV)	12
2.3. Aptamers in Diagnosis of Human Immunodeficiency Virus (HIV)	14
2.4. Aptamers in Diagnosis of Influenza	15
2.5. Aptamers in Diagnosis of Arboviruses	16
2.6. Aptamers in Diagnosis of SARS Virus	17
2.7. Aptamers in Diagnosis of Ebola Virus	18
2.8. Aptamer in Diagnosis of SARS-COV-2	18
2.9. Aptamers in Diagnosis of Human Papilloma Virus (HPV)	20
2.10. Aptamer in Diagnosis of Herpes Simplex Virus (HSV)	20
3. POTENTIALLY THERAPEUTIC APTAMERS AGAINST VIRAL PROTEINS	21
3.1. Aptamers Against Human Immunodeficiency Virus (HIV) Proteins	21
3.1.1. Reverse Transcriptase (RT)	21
3.1.2. Integrase (IN)	22
3.1.3. Other proteins of HIV-1	23
3.2. Aptamers Against Hepatitis C Virus (HCV) Proteins	24
3.2.1. Non-Structural Proteins (NS) of HCV	24
3.2.2. Structural Proteins of HCV	26
3.3. Aptamers Against Hepatitis B Virus (HBV) Proteins	26
3.4. Aptamers Against Severe Acute Respiratory Syndrome (SARS) Coronavirus Proteins	26
3.5. Aptamers Against Influenza Virus Proteins	27
4. CONCLUDING REMARKS	28
CONSENT FOR PUBLICATION	29
CONFLICT OF INTEREST	29
ACKNOWLEDGEMENTS	29
REFERENCES	29
CHAPTER 2 HOST-DIRECTED, ANTIBIOTIC-ADJUVANT COMBINATION, AND ANTIBIOTIC-ANTIBIOTIC COMBINATION FOR TREATING MULTIDRUG-RESISTANT (MDR) GRAM-NEGATIVE PATHOGENS	46
<i>Wattana Leowattana, Pathomthep Leowattana and Tawitthep Leowattana</i>	
INTRODUCTION	47
MDR GRAM-NEGATIVE PATHOGENS (GNPS)	47

MECHANISM OF RESISTANT DRUGS	48
ESBL-PRODUCING ENTEROBACTERIACEAE	49
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)	51
MDR <i>A. BAUMANNII</i>	51
HOST-DIRECTED THERAPIES	52
ANTIBIOTIC-ADJUVANT COMBINATION THERAPY	53
ANTIBIOTIC-ANTIBIOTIC COMBINATION THERAPY	55
TREATMENT OF MDR <i>K. PNEUMONIAE</i>	56
TREATMENT OF MDR <i>P. AERUGINOSA</i>	57
TREATMENT OF MDR <i>A. BAUMANNII</i>	59
TREATMENT OF MDR <i>E. COLI</i>	61
CONCLUDING REMARKS	62
CONSENT FOR PUBLICATION	63
CONFLICT OF INTEREST	63
ACKNOWLEDGEMENTS	63
REFERENCES	63

CHAPTER 3 BIOACTIVE SUBSTANCES AS ANTI-INFECTIVE STRATEGIES AGAINST	
<i>CLOSTRIDIODES DIFFICILE</i>	72
<i>Joana Barbosa and Paula Teixeira</i>	
INTRODUCTION	73
PATHOGENESIS AND EPIDEMIOLOGY OF <i>C. DIFFICILE</i>	73
CURRENT APPROACHES IN THE TREATMENT OF CDI	74
Initial Episodes of CDI	75
Fulminant Episodes of CDI	76
Recurrence of CDI	76
First Recurrence of CDI	77
Second or Subsequent Recurrence of CDI	77
Fecal Microbiota Transplantation	77
PROMISING CANDIDATE ANTIBIOTICS FOR THE PREVENTION/-TREATMENT OF	
CDI AS ALTERNATIVE TO STANDARD THERAPIES	78
Cadazolid	78
CRS3123	78
Nitazoxanide	79
Ramoplanin	79
Ridinilazole	79
Surotomycin	80
Tigecycline	80
OTHER PROMISING ANTI-INFECTIVE STRATEGIES FOR THE	
PREVENTION/TREATMENT OF CDI	80
Vaccines	81
Monoclonal Antibodies	82
Non-Toxigenic Spores	82
Bacteriophages	83
Probiotics	84
Bacteriocins	86
Lantibiotics	86
Thiopeptides	88
Sactibiotics	89
Synthetic Polymers	90
CONCLUDING REMARKS	91

CONSENT FOR PUBLICATION	92
CONFLICT OF INTEREST	92
ACKNOWLEDGEMENTS	92
REFERENCES	92
CHAPTER 4 ANTI-TOXOPLASMA DRUG DISCOVERY AND NATURAL PRODUCTS: A	
BRIEF OVERVIEW	103
<i>Jhony Anacleto-Santos, Perla Y López-Camacho, Elisa Vega-Ávila, Ricardo Mondragón-Flores, Elba Carrasco-Ramírez and Norma Rivera-Fernández</i>	
INTRODUCTION	104
ETHNOBOTANICAL RECORDS	108
<i>In vitro</i> Activity Against <i>T. gondii</i>	108
<i>Pleopeltis Crassinervata</i>	108
<i>Vernonia Colorata</i>	108
<i>Sophora Flavescens</i> and <i>Torilis Japonica</i>	109
<i>Ginkgo Biloba</i>	109
<i>Azadirachta Indica</i> and <i>Melia Azedarach</i>	109
<i>Psidium Guajava</i> and <i>Tinospora Crispa</i>	110
<i>Eurycoma Longifolia</i>	110
<i>Myristica Fragrans</i>	110
<i>Astragalus Membraneceus</i> and <i>Scutellaria Baicalensis</i>	111
<i>Sambucus Nigra</i>	111
<i>Balsamociteus Camerunensis</i>	111
<i>Jatropha Curcas</i>	111
<i>Shorgum Bicolor</i>	112
<i>Achillea Millefolium</i> and <i>hypericum Perforatum</i>	112
<i>Cola Gigantea</i> , <i>Tectona Grandis</i> and <i>Vernonia Amigdalina</i>	112
Anti- <i>T. gondii</i> <i>in vivo</i> and <i>in vitro</i> activity	113
<i>Zingiber Officinale</i> (ginger), <i>Ginkgo Biloba</i> and <i>Glycyrrhiza Glabra</i>	113
<i>Thymus Broussonetii</i>	113
<i>Bunium Persicum</i>	113
<i>Thymus Vulgaris</i>	114
<i>Echinaceae Purpurea</i>	114
<i>Nigella Sativa</i>	114
<i>Berberis Vulgaris</i> and <i>Saturja Khuzestanica</i>	115
<i>Artemisia Annu</i>	115
<i>Piper Betle</i> , <i>P. Sarmentosum</i> and <i>P. Nigrum</i>	116
<i>Allium Paradoxum</i> , <i>Feijoa Sellowiana</i> and <i>Quercus Castaneifolia</i>	116
<i>Araucaria Heteropil</i>	117
<i>Aloe Vera</i> and <i>Eucaliptus</i>	117
CONCLUDING REMARKS	122
CONSENT FOR PUBLICATION	122
CONFLICT OF INTEREST	122
ACKNOWLEDGEMENTS	122
REFERENCES	122
CHAPTER 5 DEVELOPMENT OF ANTIMALARIAL AND ANTILEISHMANIAL DRUGS	
FROM AMAZONIAN BIODIVERSITY	127
<i>Antônio R. Q. Gomes, Kelly C. O. Albuquerque, Heliton P. C. Brígido, Juliana Correa-Barbosa Maria Fâni Dolabela and Sandro Percário</i>	
INTRODUCTION	128

Chemical Studies and Evaluation of Biological Activities of Species that are more Frequently Cited in the Literature	140
CONCLUSION	161
CONSENT FOR PUBLICATION	161
CONFLICT OF INTEREST	161
ACKNOWLEDGEMENTS	161
REFERENCES	162
SUBJECT INDEX	173

PREFACE

The 7th volume of **Frontiers in Clinical Drug Research – Anti Infectives** comprises five chapters that cover a variety of topics including antivirals, treatments against some gram negative and gram negative bacteria, and an overview on a few antiprotozoal drugs that target specific pathogens.

In chapter 1, Evran *et al.*, focus on aptamers with antiviral activity, as well as the use of aptamers in viral detection platforms. They also give an overview of aptamers developed against viruses, and discuss the major hurdles in aptamer use, as well as the strategies to improve the drug potential of aptamers.

In chapter 2, Leowattana *et al.* discuss host-directed, antibiotic-adjuvant combinations and antibiotic-antibiotic combination for treating Multidrug-Resistant (MDR) gram- negative pathogens (*Acinetobacter*, *Enterobacteriaceae*, *Pseudomonas*, etc.).

In chapter 3, Barbosa and Teixeira explore the current therapeutic approaches and advances in the search for alternative solutions to inhibit the opportunistic pathogen *C. difficile*.

Rivera-Fernández *et al.* in chapter 4 of the book, review the *in vitro* and *in vivo* activities of extracts, fractions, and isolated compounds obtained from different plants against *Toxoplasma gondii*, the pathogen that causes toxoplasmosis. This chapter presents information on potential leads for novel therapeutic agents for this disease.

In the last chapter of the book by Percário *et al.*, the author describe the main Amazonian species used to treat malaria and leishmaniasis in Brazilian folk medicine, relating ethnobotanical results to chemical studies, evaluation of activities, and toxicity. Several promising compounds of plants used in traditional Amazonian medicine are described

I would like to thank all the authors for their excellent contributions that will be of great interest. Also, I would like to thank the editorial staff of Bentham Science Publishers, particularly Mr. Mahmood Alam (Editorial Director) of Bentham Science Publishers, Mr. Obaid Sadiq (In-charge Books Department) and Miss Asma Ahmed (Senior Manager Publications) for their support.

Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

- Antônio R. Q. Gomes** Post-Graduate Program in Pharmaceutical Innovation, Federal University of Pará, Belém, PA, Brazil
- Canan Özyurt** Department of Chemistry and Chemical Processing Technologies, Lapseki Vocational School, Canakkale Onsekiz Mart University, Canakkale, Lapseki, Turkey
- Elba Carrasco-Ramírez** Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Coyoacán, Mexico
- Elisa Vega Ávila** Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana, Unidad Iztapalapa, Mexico
- Ezgi Man** Department of Biochemistry, Ege University, Faculty of Science, Izmir, Turkey
- Heliton P. C. Brígido** Post-Graduate Program in Pharmaceutical Innovation, Federal University of Pará, Belém, PA, Brazil
- Jhony Anacleto-Santos** Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Mexico
Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Mexico
- Joana Barbosa** Universidade Católica Portuguesa, CBQF - Centro de Biotecnologia e Química Fina—Laboratório Associado, Escola Superior de Biotecnologia, Porto, Portugal
- Juliana Correa-Barbosa³** Post-Graduate Program in Pharmaceutical Sciences, Federal University of Pará, Belém, PA, Brazil
- Kelly C. O. Albuquerque** Post-Graduate Program in Biodiversity and Biotechnology of the BIONORTE Network, Federal University of Pará, Belém, PA, Brazil
- Merve Gültan** Department of Biochemistry, Ege University, Faculty of Science, Izmir, Turkey
- Maria Fâni Dolabela** Post-Graduate Program in Pharmaceutical Sciences, Federal University of Pará, Belém, PA, Brazil
Post-Graduate Program in Biodiversity and Biotechnology of the BIONORTE Network, Federal University of Pará, Belém, PA, Brazil
- Norma Rivera-Fernández** Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Coyoacán, Mexico
- Özge Uğurlu** Department of Biochemistry, Ege University, Faculty of Science, Izmir, Turkey
Department of Medical Services and Techniques, Hatay Vocational School of Health Services, Hatay Mustafa Kemal University, Tayfur Sökmen Campus, Alahan-Antakya/ Hatay, Turkey
- Pathomthep Leowattana** Tivanon Medical Clinics, Tivanon Road, Muang, Nonthaburi, Thailand
- Paula Teixeira** Universidade Católica Portuguesa, CBQF - Centro de Biotecnologia e Química Fina—Laboratório Associado, Escola Superior de Biotecnologia, Porto, Portugal

Perla Yolanda López Camacho	Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, Mexico
Ricardo Mondragón-Flores	Departamento de Bioquímica, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Zacatenco, Mexico
Sandro Percário	Post-Graduate Program in Biodiversity and Biotechnology of the BIONORTE Network, Federal University of Pará, Belém, PA, Brazil
Serap Evran	Department of Biochemistry, Ege University, Faculty of Science, Izmir, Turkey
Tawithep Leowattana	Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Sukhumvit 23, Wattana District, Bangkok, Thailand
Wattana Leowattana	Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Rajavithi road, Rachatawee, Bangkok, Thailand

CHAPTER 1

Nucleic Acid and Peptide Aptamers as Potential Antiviral Drugs**Serap Evran^{1,*}, Özge Uğurlu^{1,2}, Ezgi Man¹, Merve Gültan¹ and Canan Özyurt³**¹ Ege University, Faculty of Science, Department of Biochemistry, 35100, Izmir, Turkey² Department of Medical Services and Techniques, Hatay Vocational School of Health Services, Hatay Mustafa Kemal University, Tayfur Sökmen Campus 31060, Alahan-Antakya/ Hatay, Turkey³ Department of Chemistry and Chemical Processing Technologies, Lapseki Vocational School, Canakkale Onsekiz Mart University, Canakkale, Lapseki, Turkey

Abstract: Aptamers with target-specific binding properties have emerged as an alternative to antibodies. Nucleic acid aptamers are short single-stranded oligonucleotides that can fold into unique three-dimensional structures. Nucleic acid aptamers are selected from random libraries *in vitro* by using the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technology. Likewise, peptide aptamers are short peptides that can be selected *in vitro* by using different strategies including phage display, ribosome display, or mRNA display. Aptamers are superior to antibodies with regard to ease of production, high stability, small size, and low cost. Therefore, aptamers find broad use in different biotechnological and therapeutic applications. Among them, aptamer use in virus detection and antiviral therapy is one of the attractive applications. The present Covid-19 pandemic and life-threatening viral infections reveal the need for rapid therapeutic solutions that can efficiently target viral mechanisms. In this respect, the chapter is mainly focused on aptamers with antiviral activity, as well as the use of aptamers in viral detection platforms. First, we summarize aptamer selection technologies that can be performed *in vitro*. Among them, we briefly explain ribosome display, mRNA display and SELEX (Systematic Evolution of Ligands by Exponential Enrichment) technologies. Then, we review aptamers targeting viral proteins and viral invasion mechanisms. In addition, we give an overview of aptamers developed against viruses. We also discuss the major hurdles in aptamer use, as well as the strategies to improve the drug potential of aptamers.

Keywords: Antiviral aptamer, Aptasensor, Diagnostic aptamers, DNA aptamer, mRNA display, Peptide aptamer, Ribosome display, RNA aptamer, SELEX, Therapeutic aptamers.

* **Corresponding author Serap Evran:** Ege University, Faculty of Science, Department of Biochemistry, 35100, Izmir, Turkey; Tel: +90 232 3112304; Fax: +90 232 3115485; E-mail: serap.evran@ege.edu.tr

Atta-ur-Rahman, FRS (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

1. INTRODUCTION

Nucleic acid aptamers and peptide aptamers with antibody-like binding properties are promising therapeutic agents. Several aptamers are currently evaluated under clinical phase studies, but the majority of studies are focused on metabolic diseases. In this chapter, we aim to highlight the potential use of aptamers as novel antiviral agents, and their importance in diagnosis and monitoring viral infections.

The first section of the chapter gives an overview of the *in vitro* selection methods used to identify peptide and nucleic acid aptamers. Here, only some methods developed for selection from combinatorial libraries are given. This section is divided into three sub-sections as 1.1, 1.2 and 1.3 to introduce the methods of mRNA display, ribosome display and SELEX. The SELEX section is further divided into 1.4.1 and 1.4.2 to summarize two of the SELEX methods, namely cell-SELEX and bead-based SELEX. The final sub-sections 1.5 and 1.6 explore the modification strategies to improve the stability properties of aptamers for therapeutic use.

The second section of the chapter is devoted to aptamers used for the detection of viruses. The sub-sections 2.1-2.9 summarize the studies for diagnosis of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza, Arboviruses, SARS virus, Ebola Virus, SARS-CoV-2, and Human Papilloma Virus (HPV).

The third section of the chapter is devoted to the aptamers targeting viral proteins. Aptamers developed against several proteins of HIV, HCV, HBV, SARS, and Influenza are summarized under the sections 3.1-3.5.

1.1. The *in vitro* Selection Methods for Peptide and Nucleic Acid Aptamers

Directed evolution is a powerful tool to develop proteins with superior function and binding properties [1]. One critical step of directed evolution is the screening or selection of improved variants from a large library [2]. Advances in molecular techniques have allowed the design of highly diverse libraries of nucleic acids, peptides and antibodies [3]. To meet the demand for working with large libraries, protein display technologies have been developed for the selection, isolation and identification of proteins with the desired properties [4,5]. Display techniques are basically divided into two groups: (i) cell-free and (ii) cell-based. Cell-based approaches such as bacterial display, yeast display, mammalian cell display and phage display have some limitations regarding the efficiency of recovery and library diversity [6]. Although phage display has been widely used to select

proteins and peptides with improved binding properties [7], cell-free display methods have emerged as an alternative to overcome the limitations associated with living cells [8].

Ribosome display and mRNA display are cell-free methods, which rely on *in vitro* transcription and translation of the newly formed peptide along with its encoding mRNA. Thereby, ribosome display and mRNA display can establish a direct link between phenotype and genotype. *In vitro* display and selection approach consists of 3 steps: (i) designing the initial library, (ii) performing repetitive rounds to obtain the desired characteristics, (iii) screening and characterizing the selected variants [9]. Engineered antibodies, proteins, as well as peptides for various applications in diagnostics and therapeutics have been identified by *in vitro* selection methods [10]. Ribosome display and mRNA display enable identification of high-affinity proteins or peptide aptamers [11,12], whereas SELEX (Systematic Evolution of Ligands by Exponential enrichment) method allows *in vitro* nucleic acid aptamer selection. As shown in Table 1, those *in vitro* methods allow working with libraries of large size. Cell-based approaches are limited by cell growth and replication [13]. In contrast, *in vitro* selection methods allow precise control of many parameters like pH, temperature, buffer conditions, and ionic strength [14]. Auxiliary components including the binding target and reaction substrates can be easily added to the selection medium, thereby eliminating the toxic effect problem that may be encountered in cell-based display methods [15].

Table 1. Library size of *in vitro* selection methods.

<i>In vitro</i> method	Size of library	References
SELEX	10^{14} - 10^{15}	[16]
mRNA display	10^{12} - 10^{13}	[14]
Ribosome display	10^{13} - 10^{14}	[17]

1.2. MRNA Display

mRNA display is based on the formation of a covalent link between the target peptide/protein and the mRNA encoding it. For this aim, 3' end of mRNA is modified with puromycin, an antibiotic molecule that acts like an aminoacylated tRNA. Upon translation of the modified mRNA, puromycin enters the A region of the ribosome and forms a peptide bond with the C-terminal of the polypeptide. In this way, the puromycin-modified mRNA is covalently linked to the peptide [18]. This generates a stable link between genotype and phenotype. In addition, this stable covalent bond allows selection under stringent conditions. In mRNA

Host-Directed, Antibiotic-Adjuvant Combination, and Antibiotic-Antibiotic Combination for Treating Multidrug-Resistant (MDR) Gram-Negative Pathogens

Wattana Leowattana^{1,*}, Pathomthep Leowattana² and Tawithep Leowattana³

¹ Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee, Bangkok 10400, Thailand

² Tivanon Medical Clinics, 99 Tivanon Road, Muang, Nonthaburi 11000, Thailand

³ Department of Medicine, Faculty of Medicine, Srinakharinwirot University, 114 Sukhumvit 23, Wattana District, Bangkok 10110, Thailand

Abstract: Antibiotics were firstly used for the treatment of critical infections in the 1940s. They could save patients' lives and increased life spans by improving the outcome of serious infections. Antibiotics are the most commonly used drugs in a healthcare environment. However, antibiotics are not correctly prescribed, due to improper antibiotic selection, not suitable dosing, inappropriate treatment duration, and wrong treatment in nonbacterial conditions. Consequently, the rapid emergence of resistant bacteria occurs worldwide because they could adapt and compete with environmental stress. There are 4 primary mechanisms of resistance to counter the antibiotics: (i) modification of the target, (ii) enzymatic inhibition of the antibiotics, (iii) active efflux of the antibiotics, and (iv) changing membrane permeability. Carbapenem-resistant *Pseudomonas aeruginosa* (CR-PA), CR *Acinetobacter baumannii* (CR-AB), and CR *Enterobacteriaceae* were declared by World Health Organization (WHO) as the three most important pathogens that pose the greatest threat to human health. Moreover, they are also multidrug-resistant (MDR) and usually resist almost all of the most effective antibiotics, including carbapenem and fourth-generation cephalosporin. There is an urgent need to develop new strategies to combat antibiotic resistance and preserve the existing antibiotics. Numerous approaches, including host-directed, antibiotic-adjuvant combination, and antibiotic-antibiotic combination therapy, have been put forward to bring about antibiotic efficacy against MDR pathogens.

Keywords: Antibiotic-Adjuvant Combination, Antibiotic-Antibiotic Combination, Gram-Negative Pathogens, Host-Directed, Multidrug-Resistant.

* Corresponding author Wattana Leowattana: Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Tel: +6623549100, Ext. 3168; Fax: +6623549168; E-mail:wattana.leo@mahidol.ac.th

INTRODUCTION

Bacterial infections remain a significant global health problem. Antibiotics have brought about a decrease in prevalence from bacterial pathogens; however, we increasingly confront antimicrobial resistance (AMR) to these antibiotics, and the development of new antibiotics lags beyond the emergence of the bacterial resistance. The problem is not confined to human-linked habitats since different works have shown that other ecosystems, including animals, soil, and water bodies, contribute to the origin, spread, and maintenance of AMR. Moreover, multidrug-resistant (MDR) microorganisms are among the most prominent healthcare problems of the 21st century and are responsible for 60,000 - 70,000 deaths per year in the United States and Europe [1, 2]. These situations are prevalent in the low- and middle-income countries where the resistant strains are hard to detect. Recently, World Health Organization (WHO) has reported that approximately 51% and 65% of infections are resistant to penicillin and ciprofloxacin, respectively, in many countries [3]. The antibiotics are widely used in medical therapeutic facilities and selection pressure is developed that increases MDR pathogens; thus there is a further need for new-generation antibiotics with novel antibacterial properties [4, 5]. To mitigate the MDR pathogen, combination treatment is an urgent option. Combining two antibiotics comprised of a drug targeting the antibiotic resistance activity and an adjuvant are promising new therapeutic strategies [6, 7]. Furthermore, the clinical manifestation of bacterial pathogens reflects a complex interplay between the host, pathogen, and antibiotics. Owing to the innate immune response playing a crucial role in combating bacterial infection, a host-directed therapy combined with an appropriate antimicrobial agent may reduce the antibacterial resistance. This approach may lead to a successful clinical outcome and resolve antimicrobial-resistant infections, however resulting in some of the hindrances to antibiotic treatments [8, 9]. This review focused on host-directed therapies by using the immunomodulatory agents that target critical host signaling enzymes exploited by bacteria for their intracellular invasion, replication, and dissemination. We also describe the treatment of MDR Gram-negative bacterial infection with antibiotic-adjuvant combination and antibiotic-antibiotic combination.

MDR GRAM-NEGATIVE PATHOGENS (GNPS)

The number of Gram-negative bacterial infections is more than Gram-positive bacterial infections worldwide. AMR among Gram-negative bacteria is an emerging global problem because of the rapid spread of resistance mechanisms and restricted treatment regimens. Moreover, the incidence of serious infections from MDR-GNPs has increased dramatically and constituted a serious threat to

world public health in the last decade [10 - 12]. The development of MDR strains (non-susceptible to >1 agent in >3 antimicrobial categories), extensively drug-resistant (XDR) strains (non-susceptible to >1 agent in all but <2 antimicrobial categories), and pan-drug-resistant (PDR) strains (non-susceptible to all antimicrobial agents), has increased abruptly. These infections have caused increasingly worsening morbidity and mortality and escalating treatment problems. Furthermore, they also have a great economic impact on healthcare environments due to the rising costs from prolonged hospitalizations. Moreover, the alarming aspect of these is that relatively few new antibiotics have been approved in recent years [13]. GNPs are the common causes of urinary tract infections (UTIs), intra-abdominal infections (IAIs), ventilator-associated pneumonia (VAP), and septicemia. Mainly, *Klebsiella pneumoniae*, *Escherichia coli*, and *Pseudomonas aeruginosa* are significant bacteria in the hospital infection, which account for 27% of all pathogens and 70% of all GNPs, causing healthcare-related infections [14]. The most common GNP causing VAP, and the second most common bacteria causing catheter-associated UTIs, is *P. aeruginosa*. The most common GNP causing central line-associated circulatory infections is *K. pneumoniae*. The most common GNPs causing UTIs and the second most common bacteria causing all of the healthcare-associated infections are *E. coli*. A majority of the mortalities are related to MDR-GNPs infections caused by carbapenem-resistant *Enterobacteriaceae* (CRE), extended-spectrum beta-lactamase (ESBL)-producing *Enterobacteriaceae*, MDR *P. aeruginosa*, and MDR *Acinetobacter baumannii* [15 - 18].

MECHANISM OF RESISTANT DRUGS

The expression of antibiotic inactivating enzymes and non-enzymatic pathways formulates the mechanism of AMR in GNP. The mechanisms take place by increasing the intrinsic resistance due to mutations in chromosomal genes or acquired mobile genetic elements carrying resistance genes. These include aminoglycosides modifying enzymes, plasmid encoding-lactamases, or non-enzymatic mechanisms like Qnr (plasmid-borne quinolone resistance gene) for fluoroquinolone (FQ) [19 - 21]. Notably, more than 10% of the *Enterobacteriaceae* resisted 3rd generation cephalosporin, and approximately 2-7% of it resisted carbapenem. This resistance is caused by the fast distribution of extended-spectrum beta-lactamase (ESBL) producing strains Fig. (1). Additionally, the rates of carbapenem resistance for *K. pneumoniae* are more than 25%. While *P. aeruginosa* and *A. baumannii* having resistance to carbapenem account for 20 to 40% and 40 to 70%, respectively [22].

Bioactive Substances as Anti-infective Strategies Against *Clostridioides Difficile*

Joana Barbosa^{1,*} and Paula Teixeira¹

¹ Universidade Católica Portuguesa, CBQF - Centro de Biotecnologia e Química Fina—Laboratório Associado, Escola Superior de Biotecnologia, Porto, Portugal

Abstract: The incidence and severity of diarrhea associated with *Clostridioides difficile* increased exponentially worldwide until 2004. But during the last few years, a downward trend has been observed globally, except in some European countries and Asia.

Until recently, *C. difficile* was the primary cause of nosocomial infection following antibiotic exposure, presenting a high rate of mortality and morbidity. However, the emergence and spread of a hypervirulent strain (BI/NAP1/027) and an increase in the incidence of community-acquired *C. difficile* infection (CDI), especially in populations not previously considered at high risk, have contributed to alterations in the infection epidemiology. After initial treatment with broad-spectrum antibiotics, CDI recurrence is the cause of substantial morbidity, indicating that alternative strategies to the usual therapeutics are urgently needed.

Several studies have investigated probiotics to assess their preventative and/or prophylactic effects on CDI, but their use is still controversial. Other anti-infective alternatives, such as bacteriocins and phage therapy, appear as promising answers for CDI treatment.

This review explores the current therapy approaches and the advances in searching for alternative solutions to inhibit the opportunistic pathogen *C. difficile*.

Keywords: Antibiotics, Antimicrobials, Bacteriocins, Bacteriophages, *Clostridioides difficile* infection (CDI), Fecal microbiota transplantation, Fidaxomicin, Monoclonal antibodies, Metronidazole, Non-toxigenic spores, Probiotics, Recurrent CDI, Synthetic polymers, Vaccines, Vancomycin.

* **Corresponding author Joana Barbosa:** Universidade Católica Portuguesa, CBQF - Centro de Biotecnologia e Química Fina—Laboratório Associado, Escola Superior de Biotecnologia; Rua Diogo Botelho 1327, 4169-005 Porto, Portugal, Tel: +351225580001; Fax: +351225090351; E-mail: jbarbosa@porto.ucp.pt

Atta-ur-Rahman, FRS (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

INTRODUCTION

Clostridioides difficile (previously *Clostridium difficile*) [1] is a Gram-positive, endospore-forming, and toxin-producing anaerobic species. It was originally isolated from neonates' stools in 1935 [2] as an inoffensive inhabitant of commensal intestinal microbiota. However, in 1978 *C. difficile* was recognized as an important cause of antimicrobial-associated diarrhea in hospitalized individuals [3].

Spores of *C. difficile* can be found ubiquitously in the environment. Once ingested, these highly resistant spores can survive to the gastrointestinal tract barriers and remain inactive, resisting the host's immune system mechanisms. *Clostridioides difficile* produces major toxins responsible for mild-to-severe forms of gastrointestinal infections, ranging from asymptomatic intestinal colonization, self-limiting mild diarrhea to severe or life-threatening pseudomembranous colitis, toxic megacolon, sepsis, and death [4, 5]. The main predisposing factor for developing *C. difficile* infection (CDI) is antibiotic therapy, particularly with broad-spectrum antibiotics [6]. The normal gastrointestinal microbiome acts as a colonization barrier, preventing the spore's germination and their return to a toxin-producing vegetative state [5]. Disturbance of the gastrointestinal microbiome due to antibiotic exposure allows spore germination and vegetative growth of *C. difficile* [6]. Vegetative cells enter the mucus layer and adhere to intestinal epithelial cells, proliferating and colonizing the large intestine, where they produce and release toxins [7].

Gut-targeted therapies for CDI have a relatively direct effect on a mild disease. Nevertheless, the same is not often verified in patients with severe disease [8], and recurrence of CDI occurs in many patients after initial treatment with broad-spectrum antibiotics [9]. Since the main clinical challenges are the recurrence of CDI and the resistance to antibiotics currently used in the therapy, alternative therapeutic strategies are urgently needed.

This chapter intends to review the therapy approaches recommended for CDI treatment and explore the advances in searching for new therapies, emphasizing natural alternatives to currently used antibiotics to inhibit the opportunistic pathogen *C. difficile*.

PATHOGENESIS AND EPIDEMIOLOGY OF *C. DIFFICILE*

The main virulence factor mediating the pathogenesis of *C. difficile* disease is the production of two large toxins, toxin A and toxin B [10, 11], encoded by *tcdA* and *tcdB* genes, respectively. These are located within a region of the chromosome identified as pathogenicity locus or PaLoc [11]. Some strains can also produce a

binary toxin, *C. difficile* transferase (CDT) [12]. This toxin is encoded by *cdtA* and *cdtB* genes that are located outside the PaLoc region at the part of the binary toxin locus in the genome (CdtLoc) [13]. Although there is no evidence that it causes disease *per se*, this binary toxin has been associated with more severe disease [14].

Epidemiology of *C. difficile* has been changing since the mid-2000s; community-associated infections have become more frequent among younger and relatively healthy individuals due to unknown predisposing factors, antibiotic therapy, and previous hospitalization status [15, 16]. The epidemiology of *C. difficile* in children is characterized by the transient colonization of different toxigenic and non-toxigenic strains at different times [17] and, despite the severe forms of CDI are still less common in children [18, 19], rates of recurrent CDI are similar to those in adults.

The emergence and spread of a new hypervirulent *C. difficile* BI/NAP1/027 strain (characterized as BI group by restriction endonuclease analysis, North American pulsed-field type NAP1 by pulse-field gel electrophoresis, and ribotype 027 by polymerase chain reaction ribotyping) [20] may be correlated with the new epidemiology of CDI, due to its increased sporulation [21] or hyperexpression of toxins [22]. The mechanisms by which transmission occurs in the community are not yet known.

CURRENT APPROACHES IN THE TREATMENT OF CDI

Antibiotic therapy is the treatment of choice for CDI. The severity of the disease dictates the specific treatment to be used, based on guideline recommendations [17, 23]. Until recently, vancomycin (bacterial cell wall synthesis inhibition) and metronidazole (inhibition of deoxyribonucleic acid synthesis and DNA degradation) were the first-choice antibiotics. However, recurrent CDI with significant morbidity and mortality upon the cessation of their administration triggered the development of a new and specific RNA synthesis inhibitor antibiotic, fidaxomicin (previously designated as OPT-80) [24]. The use of fidaxomicin was approved in adults (May 2011) and in children (January 2020) by the US Food and Drug Administration (FDA). It does not cause significant changes to the intestinal microbiome of infected patients during [25] and after treatment [26] compared to vancomycin, resulting in lower rates of relapse. Additionally, treatment with fidaxomicin showed reduced acquisition and overgrowth of vancomycin-resistant enterococci and *Candida* spp [27], unlike the treatment with vancomycin. Frequent use of vancomycin should be avoided since it leads to increased colonization of vancomycin-resistant enterococci, increasing the CDI recurrence risk [28]. In addition to the lower cure rates in severe CDI

CHAPTER 4

Anti-Toxoplasma Drug Discovery and Natural Products: a Brief Overview

Jhony Anacleto-Santos^{1,2}, Perla Y López-Camacho², Elisa Vega-Ávila³, Ricardo Mondragón-Flores⁴, Elba Carrasco-Ramírez⁵ and Norma Rivera-Fernández^{5,*}

¹ Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana, Mexico

² Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana, Unidad Cuajimalpa, 05348 CDMX, Mexico

³ Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana, Unidad Iztapalapa, 09340 CDMX, Mexico

⁴ Departamento de Bioquímica, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Zacatenco 07360, CDMX, Mexico

⁵ Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Coyoacán, 04510 CDMX, Mexico

Abstract: *Toxoplasma gondii*, an apicomplexan protozoan that is considered an opportunistic parasite of medical and veterinary interest, causes toxoplasmosis, which may be asymptomatic in the immunocompetent host, while fatal in the immunocompromised patient. A combination of pyrimethamine-sulfadiazine is the treatment of choice; nevertheless, these two drugs produce severe side effects and are only effective against acute toxoplasmosis, hence, less toxic novel compounds with anti-toxoplasma activity are greatly needed. Natural compounds seem to be a promising source to identify lead compounds against *T. gondii*. In this review, the *in vitro* and *in vivo* activities of extracts, fractions, and isolated compounds obtained from different plants are described. In addition, some biological and pathological generalities of the parasite are reviewed as well. Data were obtained from a bibliographic search throughout digital faculty libraries, Google Scholar search engine, Science Direct, SciELO databases, and the National Center for Biotechnology Information (NCBI). Founded records include the evaluation of 58 extracts, 14 fractions, and 7 compounds belonging to 53 species of 33 plant families. Predominant studies were made on *in vivo* RH *T. gondii* tachyzoites strain and very few in *in vivo* models of both acute and chronic toxoplasmosis. Research of natural compounds against *T. gondii* deserves more attention in order to identify novel drugs useful in the control of toxoplasmosis.

* Corresponding author Norma Rivera-Fernández: Departamento de Microbiología y Parasitología, Facultad de Medicina, UNAM CDMX 01820, Mexico; E-mail: normariv@unam.mx

Atta-ur-Rahman, FRS (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

Keywords: Anti-*Toxoplasma*, Bradyzoite, Medicinal plants, Natural products, Plant extracts, *Toxoplasma gondii*, Toxoplasmicide, Tissue cysts, Tachyzoite, IC⁵⁰.

INTRODUCTION

Based on their multiple active metabolites with therapeutic properties, natural products have been used for thousands of years to treat human malaises. Nowadays, natural products are still used by approximately four out of five people worldwide as teas, tinctures, extracts or alimentary supplements. Throughout the modern history of mankind, natural compounds have been used to design novel drugs with different uses, such as antimicrobials, antipyretics, and anti-inflammatories. The main antimalarials commonly used around the world were synthesized from natural compounds. Chloroquine was developed from quinine, an alkaloid obtained from the Cinchona stem bark; artesunate and artemether were derived from an artemisinin compound found in *Artemisia annua* leaves [1 - 4]. Based on the fact that plants have been a successful source of antimalarials, the search for novel anti-*Toxoplasma* compounds from natural products has recently increased [5 - 9]. In this review, the *in vitro* and *in vivo* activities of extracts, fractions, and isolated compounds obtained from different plants are described. To better understand the need to develop new treatments, some general aspects regarding *Toxoplasma gondii* biology and toxoplasmosis control, need to be understood. These aspects are herein briefly described.

T. gondii is an apicomplexan parasite of medical and veterinary importance and perhaps the most successful and ubiquitous protozoan. During its life cycle, the parasite develops different infectious phases, as tachyzoites, tissue cysts containing bradyzoites and oocysts [10, 11]. Crescent shape intracellular tachyzoites are responsible for the acute phase of the infection and can disseminate through blood or lymph to invade all nucleated cells [11] (Fig. 1). Proinflammatory cytokines (mostly interferon-gamma) participate in a not well characterized molecular pathway that allows tachyzoites transformation into bradyzoites and tissue cysts, that are most frequently observed in the immunocompetent host brain [12, 13] (Fig. 2). The slow proliferation of bradyzoites contained in tissue cysts causes chronic infections and can eventually interconvert into tachyzoites [10]. Oocysts, which are the resistance phase of the parasite, are found in cat feces and become infectious after approximately five days in the environment withstanding extreme conditions for several months [10]. *T. gondii* is considered a food-borne parasite as it can be transmitted by the consumption of raw or poorly cooked meat infected with tissue cysts or by the ingesta of food and water contaminated with infectious oocysts [11]. Tachyzoite infections are rarely reported to occur after drinking unpasteurized milk or by

laboratory accidents. Infection can also occur by transplacental route, transplantation of infected organs or by blood transfusion. *T. gondii* life cycle can be observed in Fig. (3). Cats' hygiene habits, as well as parasites' life cycle, make direct transmission difficult. *T. gondii* infection goes clinically unnoticed in the immunocompetent host whereas it can be lethal in immunocompromised patients [14, 15]. Unspecific clinical manifestations, such as lymphadenitis, fever, odynophagia, cephalgia, myalgias, and in rare cases hepatosplenomegaly, pulmonary or cardiac symptoms are reported in the acute phase. Toxoplasmic encephalitis can lead to death in AIDS patients, while the parasite can cause abortion or malformations in the newborn [13, 16 - 18].




Fig. (1). Phase contrast image of *T. gondii* RH strain tachyzoites in Hep-2 cell culture forming rosettes inside the host cell. N Hep-2 cell nucleus, T tachyzoites. Image obtained at School of Medicine UNAM by Rivera-Fernández N.

CHAPTER 5

Development of Antimalarial and Antileishmanial Drugs from Amazonian Biodiversity

Antônio R. Q. Gomes¹, Kelly C. O. Albuquerque², Heliton P. C. Brígido¹, Juliana Correa-Barbosa¹, Maria Fâni Dolabela^{1,2} and Sandro Percário^{2,*}

¹ Post-Graduate Program in Pharmaceutical Innovation, Federal University of Pará, Belém, PA, Brazil

² Post-Graduate Program in Biodiversity and Biotechnology of the BIONORTE Network, Federal University of Pará, Belém, PA, Brazil

³ Post-Graduate Program in Pharmaceutical Sciences, Federal University of Pará, Belém, PA, Brazil

Abstract: The search for therapeutic alternatives for the treatment of malaria and leishmaniasis is particularly important, given the increase in parasitic resistance to available drugs, as well as the high toxicity of those drugs. In this context, the Amazon region can make an important contribution through its high biodiversity of plants, many of which are informally used by local populations for the treatment of malaria, and leishmaniasis. This chapter aims to describe the main Amazonian species used to treat malaria and leishmaniasis in Brazilian folk medicine, relating ethnobotanical results to chemical studies, evaluation of activities, and toxicity. Different studies report the treatment of malaria with plants, with the most cited species being *Aspidosperma nitidum* Benth. (Apocynaceae); *Geissospermum sericeum* (Sagot.) Benth & Hook (Apocynaceae); *Euterpe precatória* Mart. (Arecaceae); *Persea americana* Mill (Lauraceae); *Bertholletia excelsa* Bonpl (Lecythidaceae); *Portulaca pilosa* L. (Portulacaceae); *Ampelozizyphus amazonicus* Ducke (Rhamnaceae). Additionally, traditional Amazonian populations use plants for the treatment of wounds, a clinical aspect associated with leishmaniasis, with the most cited genus being *Copaiba* and *Jatropha*. The antileishmanial activity of copaiba oil has been demonstrated, and it seems that this activity is related to terpenes. Another genus that deserves attention is *Musa*, used for the treatment of severe wounds. The leishmanicidal activity of triterpenes isolated from *Musa paradisiaca* and its anacardic acid and synthetic derivatives, which have been used against *Leishmania infantum chagasi*, was also tested. In summary, several isolated compounds of plants used in traditional Amazonian medicine are promising as antimalarial and antileishmanial drugs.

* Corresponding author Sandro Percário: Post-Graduate Program in Biodiversity and Biotechnology of the BIONORTE Network, Federal University of Pará, Belém, PA, Brazil; E-mails: spercario49@gmail.com and percario@ufpa.br

Keywords: Amazon, *Aspidosperma nitidum*, *Bertholletia excelsa*, *Copaiba*, *Euterpe precatoria*, *Geissospermum sericeum*, *Jatropha gossypifolia*, Leishmaniasis, Malaria, Medicinal plants, *Musa parasidiaca*, *Persea americana*.

INTRODUCTION

The recognition of the environmental limits of the modern development model has imposed the need for new forms of global governance upon the planetary environment, requiring proposals for sustainable development that oppose the worsening of environmental degradation and biodiversity loss [1].

In Brazil, the Amazon region and its people have been threatened by short-sighted, profit-driven economic interests, driving the increase in deforestation in an increasingly chaotic way. According to the Real-Time Legal Amazon Deforestation Detection System (DETER), deforestation alerts were recorded in an area of 4,219.3 square kilometers in 2018, and in 2019, 9,165.6 square kilometers of forest were deforested – more than double the area recorded in the previous year.

This accelerated deforestation will probably result in the extinction of many plant species, which will have negative impacts on the culture of the use of medicinal plants by the peoples of the Amazon. In 2005, it was estimated that about 180 indigenous peoples (approximately 208,000 individuals) lived in the Amazon, in addition to 357 remaining *quilombola* (maroon) communities and thousands of rubber tapper, riverside or babassu communities [2]. In fact, in addition to its biodiversity in terms of plant and animal species, due to the different ethnicities of its peoples, the Amazon also displays a wide spectrum of cultural diversity.

As a result of this fact, another important issue arises, which is the understanding of the process of occupation of the Amazon and the impact on the health of indigenous peoples and people who settled in the region. In this sense, this process stimulated the occurrence of several epidemics and created an asymmetry in the access to health services. For example, in metropolises, such as Belém and Manaus, health services are structured, while in remote locations within the forest, due to the great difficulty of access, the only therapeutic alternative available to treat diseases has often been the use of medicinal plants [3].

Among these diseases, malaria has been affecting the Amazonian people for centuries. A study conducted in 1885 showed that the Amazon was already plagued by the disease, and the possible explanation for this fact results from the intense migration that occurred to this region in the nineteenth century, resulting from rubber extraction activities and the construction of the Madeira-Mamoré railroad. In this scenario, many immigrants ended up dying from malaria – which

is considered the second major epidemic witnessed by Osvaldo Cruz and Carlos Chagas [4]. At the same time, as opposed to the high mortality experienced by immigrants, the riverside populations survived in this hostile environment due to their ancient knowledge of many native and exotic plant species to treat malaria and its symptoms, and this medicinal information was orally transmitted from one generation to another [5].

Deforestation in the Amazon is still a serious medical and public health problem, as it creates conditions for the development of several tropical endemic diseases, such as American Tegumentary Leishmaniasis (ATL). During deforestation, the rodent population migrates to other areas in search of natural shelters, and phlebotomic fauna, which previously engaged in hematophagy using these small mammals, begin to seek out humans for this purpose [6], thus transmitting the etiological agents of various diseases, such as malaria and leishmaniasis, among others. In this context, plant species that have historically been used in Amazonian folk medicine as healing agents and for wound treatment have shown promise for the treatment of tegumentary leishmaniasis.

This chapter aims to describe the main Amazonian species that are used in folk medicine for the treatment of malaria and leishmaniasis, relating ethnobotanical results to chemical studies, evaluation of activities, and toxicity. Initially, a search was performed for ethnobotanical studies available in different databases, and species with claims of use for malaria and leishmaniasis, for wound treatment, or as healing agents were selected.

Medicinal Plants used for the Treatment of Malaria and Leishmaniasis

Ethnobotanical studies have already been conducted in some regions of the Amazon, but in other regions, there is a lack of scientific studies aimed at describing the uses of plants for medicinal purposes. A range of factors contributes to create difficulties in conducting such studies, such as the large dimension of the territory of the Brazilian Amazon, and difficulties in moving across certain regions due to the lack of connecting roads, implying the need for air transport associated with river transport, which greatly increases the cost of a study. Another important factor is the reduced number of researchers in the ethnobotany field that reside in this region, in addition to scarce funding for these studies because of public policies related to research funding in Brazil.

Notwithstanding, among the studies already published, there are reports of popular use of plants for the treatment of malaria for more than 100 plant species of the region. The most cited families were Apocynaceae, Araceae, Arecaceae, Euphobiaceae, Fabaceae, Menispermaceae, Rhamnaceae and Simaroubaceae. Table 1 summarizes the species that were mentioned in the available literature,

SUBJECT INDEX

A

- Acetogenins 147, 160, 161
 Acid 107, 141, 142, 143, 144, 148, 149, 150, 151, 154, 155, 156, 159, 160
 arachidic 159
 araquidonic 156, 159
 behenic 156, 159
 betulinic 150, 151
 caprylic 156, 159
 carboxylic harman 142, 143, 144
 cativic 151
 cauranic-19-oic 151
 clorechinic 151
 copaiferic 151
 copalic 151
 ellagic 149
 estearic 156, 159
 folinic 107
 gallic 141, 148, 149
 hardwickiic 151
 hydroxycopalic 154, 155
 linoleic 156, 159
 myristic 156, 159
 oleic 156, 159
 palmitic 156, 159
 palmitoleic 156, 159
 phydroxybenzoic 160
 Pinifolic 155
 protocatechuic 148, 149
 ursolic 150
 vanillic 149
 vernolic 156, 159
 Acidic phosphoprotein 20
 Acinetobacter-derived cephalosporinases (ADC) 51
 Acquired immune deficiency syndrome (AIDS) 14
 Actagardine 87, 89
 naturally-occurring variant 87
 Actinoplanes garbadinensis 87
 Actinoplanes liguriae 87
 Action 54, 136, 156
 inhibiting 54
 insecticide 136
 population attributes healing 156
 Activity 21, 22, 23, 24, 25, 28, 47, 54, 57, 80, 86, 89, 108, 109, 110, 112, 113, 117, 127, 141, 143, 147, 148, 149, 153, 154, 158, 160, 161
 antibiotic 57
 antibiotic resistance 47
 anti-inflammatory 141
 bacteriostatic 80, 86
 endonuclease 28
 enzymatic 21, 22
 helicase 25, 26
 leishmanicidal 127, 143, 147, 154, 158
 narrow-spectrum 89
 polymerase 24
 protease 25
 restore beta-lactam 54
 reverse transcriptase 22
 toxic 149
 toxoplasmic 108
 Acute pyelonephritis 61
 Adjuvant therapy 91
 Adolescents 76
 ADP ribosyltransferase of rifampicin 52
 Aedes aegypti 16
 Agents 10, 22, 28, 47, 48, 91, 92, 111, 129, 147, 161
 anti-inflammatory 111
 antileishmanial 147, 161
 antimalarial and antileishmanial 147, 161
 antimicrobial 47, 48
 developing anti-influenza 28
 etiological 129
 immunomodulatory 47
 leishmanicidal 161
 promising new anti-infective 92
 therapeutic 22, 91
 Alkaloids 104, 110, 143, 144, 145, 157, 158, 160, 161
 fraction of 143
 O-demethylaspidospermidine 145
 Allergic disorders 6

- Allopathic medicine 108
Aloe vera extract 117
Amastigote forms 141, 153, 154, 158
Amazonensis 141, 143, 145, 149, 151, 153, 154, 155
 leishmania 141
Amazon folk medicine 150
Amazonian 127, 129, 132, 160
 communities 160
 folk medicine 129
 medicine, traditional 127
 territories of Brazil 132
American tegumentary leishmaniasis (ATL) 129
Amino acids 4, 54
 non-natural 54
Aminoacyl tRNA synthetases 4
Aminoglycosides 48, 59
Amoxicillin 57
Analysis 6, 14, 82, 141
 flow cytometry 14
 histological 141
 planned interim 82
 protein-protein interaction 6
Angiogenesis, stimulated 141
Annual influenza outbreaks 27
Antibacterial activity 53
Antibiotic(s) 46, 47, 48, 49, 51, 52, 53, 54, 55, 57, 62, 63, 72, 73, 75, 79, 80, 83, 89, 90, 91
 adjuvant combination therapy 53
 administration program 75
 antibiotic combination 46, 47
 broad-spectrum 51, 53, 72, 73, 83
 cadazolid 80
 combination therapy 57
 conventional 52
 cyclic lipopeptide 80
 efficacy 46
 new-generation 47
 ridinilazole 79
 tested 89
Antibiotic therapy 53, 73, 74, 75, 77
 high-risk 75
Antibodies 1, 2, 6, 7, 8, 11, 12, 17, 19, 28, 81
 anti-HCV 12
Antibody 13, 17, 28
 based nanowire sensors 13
 combination 17
 production process 28
Antileishmanial 127, 143, 144, 147, 149, 151, 154, 155, 156, 160
 activities 127, 143, 144, 147, 151, 154, 155, 156, 160
Antimalarial 130, 141, 143, 145, 147, 148, 154
 activity 141, 145, 147, 154
 and antileishmanial activities 143
 properties 130, 148
Antimicrobial activity 57, 87, 88, 89, 90
 lower 88
Antimicrobial drugs 52, 56
 active 56
Antimicrobials 51, 72, 104
 baumannii resists 51
Antioxidant activity 149, 158
 protective 158
Antiparasitic 114, 143, 160, 161
 activity 114, 143, 160
Antiplasmodial effect, direct 148
Antiproliferative activity 110
Anti-toxoplasma activity 103, 122
Aptamer(s) 1, 2, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
 affinity HIV-1 RT 22
 antibody combination 20
 anti-Gag 24
 antiTAT 14
 cholesterol-conjugated 25
 conjugated 16
 developed 12, 15, 27
 high affinity 8, 26
 monomolecular Hotoda's 23
 oligonucleotide 26
 peptide and nucleic acid 2
Aptamer-based 13, 14, 15
 biosensor platforms 13
 sensor platforms 14
 SERS assay 15
Aptamer selection 1, 8, 9, 23, 29
 process 29
 technologies 1
Aptamer in diagnosis of 11, 12, 14, 15, 16, 17, 18, 20
 arboviruses 16
 ebola virus 18
 hepatitis 11, 12
 herpes simplex virus 20
 human immunodeficiency virus 14

- human papilloma virus 20
- influenza 15
- SARS Virus 17
- Araceae heteropsis 134
- Artemisia auchery 112
- Ascomycin 55
- ASPECT-nosocomial pneumonia 58
- Aspidosperma excelsum 130, 133, 136, 138, 140, 142
 - and aspidosperma nitidum 142
 - excelsum benth 133, 138
- Assay 11, 12, 13, 14, 15, 16, 17, 19, 28, 83, 110, 113
 - amplification-based 11
 - aptamer-based 16
 - enzyme-linked immunosorbent 11, 12, 14, 28
 - serum virus neutralization 19
- B**
- Bacteria 6, 8, 46, 47, 52, 91, 83
 - commensal 83
 - infect 83
 - resistant 46
- Bacterial cell wall biosynthesis 79
- Bactericidal effect 79, 80
 - concentration-dependent 80
- Bacteriocins 72, 86, 89, 90, 91
- Bacteriophages 72, 83, 84, 91
- Baumannii infections 53, 54, 56, 60
- Best available therapy (BAT) 56, 62
- BI group by restriction endonuclease analysis 74
- Blood 11, 17, 75, 104, 105 107
 - diluted defibrinated calf 17
 - cell count, white 75
 - circulation 11
 - transfusions 105, 107
- Bovine serum albumin (BSA) 16
- Broad-spectrum beta-lactamases 50
- C**
- Cancer 6, 11, 12, 20, 115
 - cervical 11, 20
 - developing liver 12
- Carbapenemases 50, 55, 56, 57, 59
 - produced 55, 57
 - serine 50
- Carbapenem 48, 50, 51, 56
 - hydrolyzing enzyme 50
 - resistance 48, 51, 56
- Carbenicillin-hydrolyzing enzymes 50
- Carboxylated magnetic nanoparticles 12
- Cell-free translation 4
- Cephalosporinases 50, 59
 - encoded AmpC 59
- Cephalosporins 52, 57
- Chagasi 127, 145, 153, 155, 158
 - leishmania infantum 127, 158
- Chenopodium ambrosioides* 139
- Chikungunya 16
- Chloroform and aqueous extracts 150
- Chromatography 7, 109, 110, 111, 112, 115
 - column 109, 110, 111, 112
 - high-performance liquid 115
- Circular dichroism (CD) 26
- Clindamycin 54, 107, 110, 120, 121
- Clones of *Plasmodium falciparum* 143, 145
- Clostridium difficile* (*C. difficile*) 72, 73, 74, 75, 76, 77, 78, 80, 82, 83, 85, 86, 88, 91, 92
 - infection (CDI) 72, 73, 74, 75, 76, 77, 78, 80, 82, 83, 85, 86, 88, 91, 92
 - transferase (CDT) 74
- Cochlospermum planchonii* 108
- Colistin 51, 54, 55, 56, 59, 60, 61, 62
 - monotherapy 56
 - treatment 59
- Colonic anastomosis 156
- Combination of 14, 59
 - antigen/antibody immunoassays 14
 - rifampicin 59
- Combination therapy 46, 55, 56, 60, 62
 - antibiotic-antibiotic 46, 55, 56, 62
 - colistin-meropenem 56
- Combretum micranthum* 118
- Computed tomography (CT) 18
- Congenital toxoplasmosis spiramycin 107
- Copaifera 136, 139, 151, 152, 154, 155, 160
 - cearensis* 155
 - langsdorffii* 139, 155
 - lucens* 155
 - marti* 139, 154, 155
 - multijuga* 155
 - officinalis* 155
 - paupera* 154, 155
 - religiosa* 154

reticulata 155
 Coronaviruses 18, 26
 proteins 26
 Covid-19 10, 11, 28
 pandemic 28
Crescentia kujete 139
 Crimean-Congo hemorrhagic fever (CCHF)
 16, 17
 Cytomegalovirus 21
 Cytotoxicity 23, 25, 52, 108, 141
 bacterium-induced 52
 low 141
 macrophage 52

D

Deaths 11, 15, 17, 47, 60, 73, 83, 105
 bacterial cell 83
 infection-related 60
 Dengue 16
 virus 16
 Detection 15, 19
 limit of aptamer-based SERS assay 15
 methods for SARS-CoV-2 19
 Diagnosis 2, 6, 7, 8, 11, 12, 13, 14, 15, 16, 17,
 18, 20
 viral infection 11
 Diarrhea 72, 73, 85, 138
 antibiotic-associated 85
 antimicrobial-associated 73
 difficile-associated 85
 Diseases 2, 6, 7, 12, 47, 73, 74, 79, 82, 91,
 108, 115, 128, 129, 136, 148, 161
 acute liver 12
 cardiovascular 82
 diarrheal 91
 endemic 129
 human respiratory 15
 infectious 6, 79
 metabolic 2, 6
 parasitic 136
 DNA 1, 12, 16, 18, 22, 25, 26, 27, 51, 74, 78,
 109
 aptamers 1, 12, 16, 18, 22, 25, 26, 27
 degradation 74
 gyrase 51
 library 5
 synthesis 78, 109
 topoisomerase IV 51
 DNA polymerase 21, 22

activity 21
 and RNase 22
 Double carbapenem (DC) 57
 Drugs 1, 6, 14, 21, 22, 26, 28, 46, 47, 51, 52,
 53, 55, 59, 82, 103, 107, 108, 122
 antibacterial 55, 82
 antiretroviral 14, 22
 anti-toxoplasma 122
 antiviral 26
 poly-cationic antimicrobial 55

E

Electrochemical impedance spectroscopy
 (EIS) 15
 Electrophoretic mobility shift assay (EMSA)
 18
 ELISA 11, 12, 13, 14, 18, 20, 28
 assays 13
 commercial 14
 Enzymes 4, 13, 19, 21, 47, 49, 50, 55, 59, 158
 acetylcholinesterase 158
 aminoglycoside-modifying 59
 chromosomal 50
 critical host signaling 47
 hydrolyzing 50
 immunoassay 19
 linked aptasorbent assay (ELASA) 13
 phosphatase 55
 ESBL 49, 58
 enzymes 58
 producing enterobacteriaceae 49
Escherichia coli 48
 European medicines agency (EMA) 61, 62
 Extended-spectrum beta-lactamase (ESBLs)
 48, 50

F

FDA and european medicines agency 61
 Fecal microbiota transplantation (FMT) 72,
 75, 77, 78, 84, 91
Feijoa Sellowiana 116, 118
 Field-effect transistor (FET) 16
 Flavopereirine 143, 144, 145
 alkaloids 145
 Fluorescence 8, 26
 activated cell sorter (FACS) 8
 resonance energy transfer (FRET) 26

Fluoroquinolone 48, 51, 57, 59, 78
resists 51
Food and drug administration (FDA) 52, 62,
74, 76, 77, 91

G

Gag 24
polyprotein 24
protein 24
Galocatechin 148, 149
Gastric ulcers 138
Gastrorrhaphy 156
Gel electrophoresis 26, 27, 74
agarose 26
pulse-field 74
Gingko biloba 121
Gram-negative bacteria 47, 49, 53, 54, 62
fight MDR 53
Gram-negative bacterial 47, 53
biofilms 53
infections 47
infections 47
Green fluorescent protein (GFP) 111

H

HBsAg-expressing hematoma cell 26
Healing 129, 136, 138, 141, 147, 151, 156,
160
activity 141, 156
agents 129, 151, 160
wound 136
Healing process 158, 161
wound 158
Hepadnaviridae family 11
Hepatitis 2, 11, 12, 13, 17, 24, 25, 26
B Virus (HBV) 2, 11, 12, 26
C Virus (HCV) 2, 12, 13, 24, 26
delta virus (HDV) 25
Herpes simplex virus (HSV) 20
Herpesviridae family 20
High-performance liquid chromatography
(HPLC) 115
HIV-1 9, 23, 24
Gag protein 24
genome 9
infection 23
replication 23, 24

HIV-1 integrase 22, 23
activity 22
inhibitors 23
HIV-2 antibodies 14
Homoorientin 147, 148
Hospital-acquired pneumonia (HAP) 49, 58
Host-directed therapies (HDTs) 47, 52, 53
HPV infections 20
Human 2, 11, 14, 19, 20, 21, 23, 111
cell receptors 21
cervical carcinoma 111
coronaviruses 19
foreskin fibroblasts (HFF) 111
Immunodeficiency Virus (HIV) 2, 11, 14,
21, 23
papilloma virus (HPV) 2, 20
Hybridization technique 53

I

Immune response 28, 81
undesired 28
Immune system 9, 13, 14, 20, 52, 73
mechanisms 73
suppressed 13
Infections 10, 11, 12, 18, 19, 20, 21, 22, 46,
47, 48, 49, 52, 54, 55, 56, 57, 58, 59, 61,
62, 72, 73, 74, 83, 104, 107, 116
acute 107
antimicrobial-resistant 47
bacterial 47, 52, 54, 55, 62
bloodstream 49, 61
bone 58
chronic 12, 104, 107
community-associated 74
gastrointestinal 73
healthcare-associated 48, 59
healthcare-related 48
invasive 57
life-threatening 59
lysogenic 83
nosocomial 72
pulmonary 55
Infectious cell culture system 26
Influenza 2, 11, 15, 16, 27, 28
detect 16
surface glycoproteins 27
virus 27, 28
viruses, human 28
virus proteins 27

- Inhibitor(s) 22, 50, 52, 111, 112
 beta-lactamase 50
 protease 111
 pyrimidine synthesis 52
 resistant TEM (IRT) 50
Intra-abdominal infections (IAIs) 48, 80
- L**
- Leishmania donovani* 146
Leishmaniasis 127, 128, 129, 136, 138, 140, 160, 161
Life-threatening viral infections 1
Locked nucleic acid (LNA) 9
- M**
- Macrophages 52, 53, 117, 141
 intraperitoneal 117
 murine lung 53
Malaria 127, 128, 129, 130, 131, 132, 133, 136, 140, 145, 149, 159, 160, 161
 treatment of 127, 129, 130, 131, 132, 133, 136, 160
MDR *Acinetobacter baumannii* 48
Mechanisms 1, 28, 48, 49, 51, 52, 57, 74, 110, 113
 acquired enzymatic 57
 complementary 53
 nonenzymatic 48
 targeting novel virulence 28
 viral invasion 1
Medical therapeutic facilities 47
Medicinal plants 104, 108, 112, 113, 114, 122, 128, 129, 161
 endemic 113
Megastigmane glycosides 145
Meropenem-vaborbactam therapy 56
Metabolites 104, 149, 156, 158
 multiple active 104
 secondary 149
Metallo-beta-lactamase (MBL) 50, 51
Microbiome, gastrointestinal 73
Microbiota, intestinal 73
Microorganisms 47, 84
 live 84
Minimum inhibitory concentration 87
Mirror image transformation 10
Mitochondrial dysfunction 149
Modest 160, 161
 antiparasitic activity 160
 antiplasmodial activity 160, 161
 leishmanicidal activity 160
Molecular 2, 23
 docking studies 23
 techniques 2
Monoclonal antibodies 14, 72, 80, 82, 91
 human 82
Monotherapy 55, 56
mRNA 3, 5
 encoding 3, 5
 nuclease-hypersensitive 5
 puromycin-modified 3
MTT 113, 116, 117
 assay 113, 116
 method 117
- N**
- Nasopharyngeal aspirate 19
Natural defense systems 52
Nebulized colistin regimen 61
Nosocomial pneumonia (NP) 58, 59
Nucleases 9, 28
Nucleic acid aptamers 1, 2, 6, 10, 15
Nucleocapsid 17, 19, 26
 assembly, inhibiting 26
- P**
- P. aeruginosa* infection 53
Pan-drug-resistant (PDR) 48
Parasite 110, 112
 inhibition 112
 invasion 110
Parasitemia 143
Pathogens, opportunistic 72, 73
Penicillin-binding proteins (PBPs) 54
Peptides 2, 3, 6, 7, 9, 10, 17, 52, 53, 54, 86, 87, 90, 91
 antimicrobial 53, 86
 heat-stable 86
 host-defense 90
Phospho-acetyl-L-aspartate (PALA) 52, 53
Plants 103, 104, 108, 109, 111, 112, 127, 128, 129, 132, 133, 138, 148, 149, 157
 peripheral economies use 108
 traditional Amazonian populations use 127

- Pneumonia 48, 49, 56, 58, 59, 80
 community-acquired 80
 healthcare-related 49
 nosocomial 58, 59
 ventilator-associated 48
- Polymerase chain reaction (PCR) 11
- Post-SELEX Modifications 7, 9, 22
- Production 18, 25, 49, 51, 55, 57, 59, 73, 81, 89, 90, 113, 116
 antibody 18
 beta-lactamase 49, 55
- Properties 2, 5, 7, 9, 15, 22, 47, 111, 113, 158
 antifungal 113
 anti-hemorrhoid 111
 anti-leukemic 111
 leishmanicidal 158
 novel antibacterial 47
- Proteases 10, 24, 25, 28
 viral 24
- Proteins 2, 3, 4, 5, 6, 7, 9, 10, 14, 16, 17, 18, 19, 20, 23, 24, 26, 27, 54, 78, 80, 111
 aptamer-target 9
 essential viral regulatory 23
 genetic fusion 10
 green fluorescent 111
 nucleocapsid 17, 19, 24
 of SARS coronavirus 19, 26
 penicillin-binding 54
 streptavidin-fused replication 16
 synthesis 4, 5, 78, 80
- Proteolysis 90, 112
 extracellular 112
- Q**
- Quartz crystal microbalance (QCM) 14
- Quinolone resistance-determining regions (QRDRs) 51
- R**
- Reactive oxygen species (ROS) 149
- Receptor binding domain (RBD) 20, 27
- Regimen, carbapenem-carbapenem combination 57
- Resistance 9, 10, 46, 47, 48, 49, 51, 52, 53, 54, 57, 59, 73, 90, 107, 127
 aminoglycoside 51
 antibacterial 47
 antimicrobial 47
 beta-lactam 49
 combat antibiotic 46
 developing drug 52
 intrinsic 48, 54
 microbial 52
 nuclease 9, 10
 parasitic 127
- Restriction endonuclease analysis 74
- Retroviral integrase 22
- Reverse 18, 21, 22
 transcriptase (RT) 21, 22
 transcription polymerase chain reaction 18
- Rev-host protein interactions 23
- Rift valley fever virus (RVFV) 17
- RNA 13, 15, 23, 25
 fluoropyrimidine-containing 23
- RNA aptamers 13, 14, 17, 18, 20, 22, 23, 24, 25, 26, 27
 cholesterol-conjugated 25
 pyrimidine-modified 25
 targeting 26
- RNA-dependent RNA polymerase 24
- S**
- SARS-CoV helicase 26, 27
- SARS 2, 17, 19
 outbreak 17, 19
 virus 2, 17
- SELEX 1, 2, 3, 6, 7, 9, 12, 19, 20
 capillary electrophoresis 7
 medium 6
 section 2
 silico 7
 technology 7
- SELEX methods 2, 8, 9
 conventional 9
- Serological tests 12
- Serum 12, 16, 17, 19, 20, 28, 29, 75, 76, 88
 creatinine level 75, 76
 fetal bovine 12
 human 17
- Severe acute respiratory syndrome (SARS) 2, 17, 26
- Short linear antibacterial peptide (SLAP) 54
- Spectroscopy 15, 26
 electrochemical impedance 15
- Sporozoites 150
- Staphylococcus* 51, 86, 87

aureus 51
mutans 87
thermophilus 86
Streptomyces hygroscopicus 55
 Sulfadiazine-pyrimethamine (SP) 114
 Surface-enhanced raman scattering (SERS)
 15, 16
 Surface plasmon resonance (SPR) 7, 14, 27
 developed aptamer-based 14
 Surgical wound infections 49
 Survival 88, 90, 112, 113, 116, 117
 difficile spore 90
 Suspected CRE infection 56
Symphytum officinale 139
 Synergistic antibiotic effect 53
 Synthesis 23, 25, 74, 78, 90, 108, 161
 deoxyribonucleic acid 74
 intracellular RNA 25
 Synthetic 72, 78, 90
 diaryldiamine 78
 polymers 72, 90

T

Tachyzoites 104, 105, 110, 114, 115, 116, 117
 intracellular 104, 116
 liver 114
 spleen 115
 TAR-dependent transcription 9
 Targeting viral proteins 1, 2
 Technologies, protein display 2
 Therapeutic aptamers 1, 21
 Therapy 1, 8, 12, 55, 61, 72, 73, 83, 84
 antimicrobial 55
 antiviral 1
 intravenous 61
 phage 72, 84
 Thermal stability 9
 Thick borne encephalitis virus (TBEV) 16, 17
 Thioaptamer 22
 Thiopeptides 88, 90
 Thrombocytopenia 107
 Thymus broussonetii extracts 114, 119, 122
Tinospora crispa 110, 119, 122
 Toxins 7, 8, 73, 74, 78, 81, 82, 83, 89, 90
 binary 74
 genes encoding 83
 Toxoid vaccines 81
Toxoplasma gondii 103, 104
 Toxoplasmic encephalitis 105

Toxoplasmodicidal 112, 116
 activity 116
 candidates 112
 Toxoplasmodicide activity 110
 Toxoplasmosis 103, 107, 108, 113, 114
 acute 103, 113
 chronic 103, 114
 treatment 107
 Traditional 108, 111
 Chinese medicine 111
 West African medicine 108
 Trans-activating responsive (TAR) 9
 Translation system 4
 Transmission 16, 20, 74, 105, 107, 110
 direct 105
 electron microscopy 110
 pathway 16
 vertical 107
 Transplacental route 105
 Treatment 127, 129, 136, 140, 151, 158, 160,
 161
 of malaria and leishmaniasis 127, 129,
 140, 160, 161
 of severe wounds 127, 158
 wound 127, 129, 136, 151
Trypanosoma cruzi 114
 trypanothione reductase 147
 Tumor necrosis factor (TNF) 116

U

Urinary tract infections (UTIs) 48, 49
 UTIs, catheter-associated 48

V

Vaccines 21, 72, 81, 91
 formalin-inactivated toxoid-based 81
 Vancomycin 72, 74, 75, 76, 77, 78, 79, 80, 84,
 85, 87, 88, 89, 90, 91
 oral 76, 77, 79, 80
 rectal 76
 resistant enterococci 74, 79
 VAP treatment 59, 60, 61
 Ventilator-associated pneumonia (VAP) 48,
 56, 58, 60
 Vero cells 109, 110, 111, 116
 Viral 10, 24, 27, 28
 diagnosis 10

- genomic RNA levels 24
- infection, inhibited 27, 28
- Virus(s) 1, 2, 6, 7, 8, 10, 11, 12, 16, 17, 18,
20, 21, 24, 25, 26, 27, 28, 83
 - double-stranded DNA 11
 - double-stranded small DNA 20
 - enveloped RNA 12
 - infectious 25
 - like particles (VLPs) 24
 - polymerase 28
 - proteins 17
 - replication 12
 - single-stranded RNA 18

W

- Waals interactions 6
- Western-blot analysis 25
- West Nile virus (WNV) 16, 17
- World health organization (WHO) 15, 46, 47,
84, 108
- Wounds, surgical 138

X


- Ximenia americana* 108, 120

Y

- Yellow fever 16

Z

- Zika virus 16, 17
- Zingiber Officinale* 113, 120



PROF. DR. ATTA-UR-RAHMAN, *FRS*

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.